[Immunogenicity of a recombinant vaccine against viral hepatitis B].
The introduction in Italy of recombinant DNA hepatitis B vaccines has allowed to plan out a very important programme of vaccination; in Italy the compulsory vaccination against hepatitis B virus begun from 1991. Because of the reduction of vaccine cost, the screening for serum markers of HBV infection is needless. On the contrary, the test of antiHBs titres after the vaccination is important in order to take into account a booster vaccine dose and to carry out revaccination strategies. In this study, we analyzed 419 subjects vaccinated with Engerix-B; the immune response was correlated with private and behaviour data.
Russo
R
R
Dipartimento di Igiene e Medicina di Comunità, Facoltà di Medicina e Chirurgia, Università degli Studi, Torino.
Ripa
F
F
Ditommaso
S
S
Zotti
C
C
Moiraghi Ruggenini
A
A
D000328:Adult; D015992:Body Mass Index; D005260:Female; D006508:Hepatitis Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D008297:Male; D014614:Vaccines, Synthetic / Q000276:immunology*
D006508:Hepatitis Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic
Analisi dell'immunogenicità di un vaccino recombinante anti-epatite virale di tipo B.